Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
27,995,500
-
Total 13F shares
-
47,940,360
-
Share change
-
-13,706,189
-
Total reported value
-
$259,939,712
-
Put/Call ratio
-
228%
-
Price per share
-
$5.45
-
Number of holders
-
96
-
Value change
-
-$112,363,836
-
Number of buys
-
61
-
Number of sells
-
40
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q2 2021
As of 30 Jun 2021,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) was held by
96 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
47,940,360 shares.
The largest 10 holders included
FMR LLC, Bain Capital Life Sciences Investors, LLC, BlackRock Inc., Ally Bridge Group (NY) LLC, VANGUARD GROUP INC, Omega Fund Management, LLC, Samsara BioCapital, LLC, ORBIMED ADVISORS LLC, Artal Group S.A., and Altium Capital Management LP.
This page lists
96
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.